TNFRSF8 and peripheral neuropathy: In a report evaluating the safety and efficacy of extended administration of BV beyond 16 cycles (24 of median cycles, range 17-42) in patients with relapsed or refractory CD30-positive lymphoma, peripheral neuropathy was the most common adverse event, with 74% of any grade and 11% of grade 3 and more [10].